P0586 Nationwide population-based cohort study on the use and persistence of infliximab (IV and SC) in France: the Riposte IBD study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjae190.0760
Abstract: Subcutaneous infliximab (IFX-SC) is available in France since 2021. Beyond the pivotal trials, real-life data is needed. The aim of the RIPOSTE study is to evaluate the real-life use of IFX-SC in France at a… read more here.
Keywords: initiation group; ifx; group; infliximab ... See more keywords